The Alzheimer’s disease biomarker market is experiencing steady growth, driven by the rising prevalence of Alzheimer’s disease and dementia, increasing emphasis on early and accurate diagnosis, and the growing adoption of biomarker-based approaches in disease management. The market is also benefiting from rapid advancements in blood-based biomarkers, particularly phosphorylated tau (p-tau) and amyloid-beta assays, which offer less invasive and more accessible alternatives to cerebrospinal fluid testing and PET imaging.
The Alzheimer’s disease biomarker market is experiencing steady growth, driven by the rising prevalence of Alzheimer’s disease and dementia, increasing emphasis on early and accurate diagnosis, and the growing adoption of biomarker-based approaches in disease management. The market is also benefiting from rapid advancements in blood-based biomarkers, particularly phosphorylated tau (p-tau) and amyloid-beta assays, which offer less invasive and more accessible alternatives to cerebrospinal fluid testing and PET imaging.